Nevakar is a specialty pharmaceutical company focused on developing injectable and ophthalmic products to address unmet medical needs in these areas. Their portfolio includes targeted therapies aimed at improving patient outcomes in conditions requiring precise delivery mechanisms.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many existing injectable drugs are supplied in formats that are not ideal for administration, requiring reconstitution or manipulation that can introduce errors or compromise sterility. These drugs often have limited room-temperature stability, necessitating refrigerated storage and complex cold-chain logistics.
Solution
Nevakar Injectables reformulates and commercializes sterile injectable drugs into enhanced dosage forms, such as ready-to-use infusion bags and pre-filled syringes, improving convenience and safety for healthcare providers. The company focuses on converting existing drug vials into standard-of-care formats with intellectual property protection. Nevakar's products feature extended room-temperature shelf life (18-24 months), reducing the need for refrigerated storage and simplifying supply chain management. They pursue FDA approval via the 505(b)(2) regulatory pathway.
Target Audience
The primary customers are hospitals, clinics, and other healthcare providers who administer injectable medications, as well as pharmaceutical companies seeking to expand their product portfolios with value-added formulations.
Features
- Reformulation of existing injectable drugs into ready-to-use infusion bags and pre-filled syringes
- Extended room-temperature stability (18-24 months) for simplified storage and logistics
- IP-protected dosage forms
- FDA approval via the 505(b)(2) pathway
- Stability studies to ensure product integrity